Skip to content
value.today

NBO Pharma Inc.

🇺🇸 Bedford, New York, USAPharmaceuticalsFounded 2021

Formerly NBO Pharma LLC

Total raised
$8 M
1 round on record
Latest round
$8 M
Jun 2025
First round on record
Jun 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of NBO Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$8 MNo. 1$2 to $10 million

NBO Pharma Inc.: Raise no. 1, Jun 2025

Investors in this round

93 investors had bought by the notice of Jan 22, 2026: 93 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$946,978
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fredric David Price · Executive Officer, Director
  • Bard David Geesaman · Director
  • Colin David Foster · Director
  • Robert David Friedman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Portland, OregonSold in AL, AZ, CA, CO, CT, DC, DE, FL, GA, IA, IL, IN, KS, MA, MD, MI, MN, MO, MS, MT, NC, ND, NH, NJ, NV, NY, OH, OK, OR, PA, SC, SD, TX, UT, VA, WA

Remarks in the notice

  • On fees: “Issuer provided placement agent (i) 13% of gross proceeds received from qualifying investors (ii) a $35,000 non-accountable expense fee and (iii) a number of warrants equal to 15% of the total number of shares sold to qualifying investors in the offering.”
  • On the amounts: “The total amount sold includes (i) $625,000 from conversion of SAFES and (ii) $7,015,217 from cash investment.”

Signed by Fredric D. Price, Chief Executive Officer. Newest notice filed Jan 22, 2026. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NBO Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2026).

    SEC Form D · Jan 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of NBO Pharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NBO Pharma Inc.
NameRoleNamed in
Fredric David PriceExecutive officerJan 2026
Bard David GeesamanDirectorJan 2026
Colin David FosterDirectorJan 2026
Fredric David PriceDirectorJan 2026
Robert David FriedmanDirectorJan 2026